The Children’s Tumor Foundation has placed an emphasis on fostering relationships and collaborations between NF experts and research companies, a priority that is delivering. Kolltan Pharmaceuticals recently announced that it is preparing to submit an IND (Investigational New Drug) application to the FDA in 2016 for a novel therapeutic KTN0158, an anti-KIT monoclonal antibody. Dr. Bruce Korf, leading NF clinician and member of the Children’s Tumor Foundation Board of Directors, initially connected Kolltan Pharmaceuticals with the Foundation.
It is exciting and encouraging to see the list of companies and novel therapeutics that we are attracting to the NF field is increasing. Since 2014, CTF has offered a service to those companies with compounds that could benefit NF research. CTF works with the company to make sure that they have access to key NF opinion leaders with the best expertise and most appropriate cell and/or animal models. In some instances, we’ve also identified the compounds, contacted the company and set up a network of KOLs-industry scientists.
Once the compound makes it through the preclinical pipeline, CTF is available to support the process of facilitating that the right patient gets the right drug at the right moment in his/ her treatment.
Click here to read more about Kolltan Pharmaceuticals’ announcement.
